Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia by Rui Zhang, Yifan Zhao, Xiao Chai, Yingshuai Wang, Mohan Zhao, Shujing Guo, Yu Zhang, Mingfeng Zhao

“…CLL1 Chimeric antigen receptor T-cell (CAR-T) therapy, as a promising immunotherapeutic approach, has demonstrated its potential to enhance the prognosis of patients diagnosed with acute myeloid leukemia (AML). …”
Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

“…Background Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. …”
Get full text

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial by Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama S. Gergis, Martin E. Guiterrez, Ran Reshef, Sumit K. Subudhi, Céline F. Jacquemont, Joseph H. Senesac, J. Henri Bayle, Charity D. Scripture, Monica S. Chatwal, Mehmet A. Bilen, Walter M. Stadler, Carlos R. Becerra

“…These results suggest that pharmacological activation of GoCAR-T® cells is feasible and may offer a promising avenue to control chimeric antigen receptor-T cell activity with continued dose-optimization to improve tolerability.…”
Get full text

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL by Willem P. J. Cox, Noël M. M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen

“…Abstract: Loss of p53 function predicts a dismal outcome in relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Chimeric antigen receptor T-cell (CAR T) therapy was recently approved to salvage relapsed/refractory BCP-ALL. …”
Get full text

Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract by Lixia Ma, Yimeng Dou, Rui Liu, Teng Xu, Fan Yang, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui Shi, Fei Xue, Biping Deng, Xiaoyan Ke, Kai Hu

“…ABSTRACT Objective Currently, chimeric antigen receptor T‐cell (CART) therapy represents a highly effective approach for relapsed/refractory B‐cell lymphomas. …”
Get full text

Engineering of SauriCas9 with enhanced specificity by Xiaoqi Zhang, Chen Tao, Miaomiao Li, Sufang Zhang, Puping Liang, Yan Huang, Huihui Liu, Yongming Wang

“…To validate its efficacy, we employed SauriCas9-R253A to disrupt three genes (B2M, TRAC, and PDCD1), a strategy integral to the development of allogeneic chimeric antigen receptor T cell (CAR-T) therapies. Our results demonstrated that the most efficient single-guide RNAs for SauriCas9-R253A exhibited comparable activity to SpCas9 and showed no detectable off-target effects in the disruption of these genes, highlighting its therapeutic potential.…”
Get full text

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience by Aaron Trando, Farid Ghamsari, Philip Yeung, Caitlin Costello, Ila Saunders, Ah-Reum Jeong

“…<b>Background/Objectives:</b> Idecabtagene vicleucel (ide-cel), an anti-B-cell maturation chimeric antigen receptor T-cell therapy, represents an unprecedented treatment option for relapsed/refractory multiple myeloma (R/R MM). …”
Get full text

Nucleotide receptor P2X7/STAT6 pathway regulates macrophage M2 polarization and its application in CAR-T immunotherapy by Qin Si, Lu Yang, Jie Liu, Hui Liu, Ruifang Bu, Na Cui

“…Background: A key factor underlying the failure of Chimeric Antigen Receptor-T Cell (CAR-T) therapy in ovarian cancer (OC) is the presence of an immunosuppressive tumor microenvironment, which is intricately linked to M2 polarization among tumor-infiltrating macrophages. …”
Get full text

Unveiling causal immune cell–gene associations in multiple myeloma: insights from systematic reviews and Mendelian randomization analyses by Hui Zhang, Hui Zhang, Ling Zhang, Jing-Xuan Lian, Zhi-Fu Kou, Yu Zhu, Yu Zhu, Li-Tian Ma, Li-Tian Ma, Jin Zheng, Jin Zheng, Can-Jun Zhao, Can-Jun Zhao

“…BackgroundThe efficacy of novel chimeric antigen receptor T-cell (CAR-T) therapy is inconsistent, likely due to an incomplete understanding of the tumor microenvironment (TME). …”
Get full text

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells by Shuxian Zhu, Shiyu Zuo, Chuo Li, Xingjie You, Erlie Jiang, Xiaoming Feng, Yuechen Luo

“…We performed cytotoxicity, proliferation, and cytokine assays to evaluate the functionality of universal chimeric antigen receptor-T cell (UCAR-T) cells and conducted in vitro and in vivo assays, including allogeneic responses and RNA sequencing, to assess their resistance to allogeneic T and NK cells, anti-leukemia efficacy, and persistence in treating hematologic malignancies. …”
Get full text

Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma by Junchen Liu, Junchen Liu, Kun Dai, Kun Dai, Muhammad Auwal Saliu, Muhammad Auwal Saliu, Mansur Dabai Salisu, Mansur Dabai Salisu, Jiangyu Gan, Lukman Olalekan Afolabi, Dehong Yan, Guizhong Zhang, Maoxuan Liu, Maoxuan Liu, Xiaochun Wan, Xiaochun Wan

“…Chimeric antigen receptor T-cell (CAR-T) therapies have shown promise in glioblastoma clinical studies, but responses remain inconsistent due to heterogeneous tumor antigen expression and immune evasion post-treatment. …”
Get full text

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell a... by Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík

“…Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the risk factors for rapid progression and further treatment. …”
Get full text

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study by Fiona Reid, Sophie Papa, John Maher, Jean-Pierre Jeannon, James Spicer, Victoria Gibson, Selvam Thavaraj, Michael Metoudi, Christopher Fisher, Nicholas Beckley-Hoelscher, Andrew Hope, Maria Elstad, Antonella Adami, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Gary J R Cook, Ana C Parente-Pereira, David M Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano

“…To target upregulated ErbB dimer expression in this cancer, we developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) approach named T4 immunotherapy. …”
Get full text

Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review by Marco Ruella, Guido Ghilardi, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, Lena E. Winestone, Alfred L. Garfall

“…Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. …”
Get full text

Application of adoptive cell therapy in malignant melanoma by Qianrong Hu, Jiangying Xuan, Lu Wang, Kangjie Shen, Zixu Gao, Yuhong Zhou, Chuanyuan Wei, Jianying Gu

“…This review discusses the application, efficacy, limitations, as well as future prospects of four commonly utilized approaches -including tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR) T cell, engineered T-cell receptor T cells, and chimeric antigen receptor NK cells- in the context of malignant melanoma.…”
Get full text

New developments in immunotherapy for SCLC by Zhonglin Hao, Tsering Dolkar, Christopher Gates, Reinhold Munker

“…Three emerging therapeutic options include bispecific T cell engagers targeting DLL3, chimeric antigen receptor T cells (CAR-T cells), and antibody–drug conjugates. …”
Get full text

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies by Mathieu Ferrari, Matteo Righi, Vania Baldan, Patrycja Wawrzyniecka, Anna Bulek, Alexander Kinna, Biao Ma, Reyisa Bughda, Zulaikha Akbar, Saket Srivastava, Isaac Gannon, Mathew Robson, James Sillibourne, Ram Jha, Mohamed El-Kholy, Oliver Muhammad Amin, Evangelia Kokalaki, Mohammed Amin Banani, Rehan Hussain, William Day, Wen Chean Lim, Priyanka Ghongane, Jade R. Hopkins, Dennis Jungherz, Marco Herling, Martin Welin, Sachin Surade, Michael Dyson, John McCafferty, Derek Logan, Shaun Cordoba, Simon Thomas, Andrew Sewell, Paul Maciocia, Shimobi Onuoha, Martin Pule

“…This permits generation of paired reagents (chimeric antigen receptor-T cells) specific for TRBC1 and TRBC2, with preclinical evidence to support their efficacy in T cell malignancies.…”
Get full text

CAR-T cells: prospective genetic engineering approach to orchestrate solid tumor in lung cancer by Angeline Felisca Tanujaya, Dhea Anggraini, Ahmad Dzulfikri Nurhan

“…Developing technology leads to innovation of cancer-targeted therapy as an ideal strategy. Chimeric antigen receptor T cells (CAR-T cells) are one of the novel immunotherapy approaches in genetic engineering. …”
Get full text

Targeting BCMA in multiple myeloma: designs, challenges, and future directions by Yi Hu, Yuetao Xie, Xiaodong Wang, Lufeng Yang, He Geng, Zugang Yi, Yao Zhang, Lin Ma, Fang Chen

Get full text